<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="58193"><DrugName>amifampridine phosphate</DrugName><DrugNamesKey><Name id="43034079">Firdapse</Name><Name id="43034082">Zenas</Name><Name id="42874481">amifampridine</Name><Name id="42924992">amifampridine phosphate</Name></DrugNamesKey><DrugSynonyms><Name><Value>3,4-diaminopyridine phosphate</Value></Name><Name><Value>3,4-DAP</Value></Name><Name><Value>3,4-diaminopyridine</Value></Name><Name><Value>amifampridine</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>amifampridine phosphate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>Firdapse</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Zenas</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>446254-47-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>54-96-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23948">Assistance Publique Hopitaux de Paris</CompanyOriginator><CompaniesPrimary><Company id="25861">BioMarin Pharmaceutical Inc</Company><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1031239">EUSA Pharma USA</Company><Company id="1050402">Huxley Pharmaceuticals Inc</Company><Company id="23948">Assistance Publique Hopitaux de Paris</Company><Company id="28650">OPi SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="58193" type="Drug"><TargetEntity id="126664" type="siDrug">Amifampridine</TargetEntity><TargetEntity id="427501" type="siDrug">Amifampridine phosphate</TargetEntity></SourceEntity><SourceEntity id="1031239" type="Company"><TargetEntity id="4297531716" type="organizationId">Jazz Pharmaceuticals (Eusa Pharma) Inc</TargetEntity></SourceEntity><SourceEntity id="1050402" type="Company"><TargetEntity id="5000469629" type="organizationId">Huxley Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="23948" type="Company"><TargetEntity id="4296543185" type="organizationId">Assistance Publique Hopitaux de Paris</TargetEntity></SourceEntity><SourceEntity id="25861" type="Company"><TargetEntity id="4295912660" type="organizationId">Biomarin Pharmaceutical Inc</TargetEntity></SourceEntity><SourceEntity id="28650" type="Company"><TargetEntity id="4297830478" type="organizationId">Jazz Pharmaceuticals France SAS</TargetEntity></SourceEntity><SourceEntity id="30089" type="Company"><TargetEntity id="4295902234" type="organizationId">Catalyst Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1836" type="ciIndication"><TargetEntity id="I95.1" type="ICD10"/><TargetEntity id="10031127" type="MEDDRA"/><TargetEntity id="D007024" type="MeSH"/><TargetEntity id="-1552133736" type="omicsDisease"/><TargetEntity id="252" type="siCondition"/></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"/><TargetEntity id="10028245" type="MEDDRA"/><TargetEntity id="D009103" type="MeSH"/><TargetEntity id="-1241225595" type="omicsDisease"/><TargetEntity id="112" type="siCondition"/></SourceEntity><SourceEntity id="2699" type="ciIndication"><TargetEntity id="G70.80" type="ICD10"/><TargetEntity id="D015624" type="MeSH"/><TargetEntity id="43393" type="ORPHANET"/><TargetEntity id="-704299533" type="omicsDisease"/><TargetEntity id="156" type="siCondition"/></SourceEntity><SourceEntity id="3252" type="ciIndication"><TargetEntity id="H55.0" type="ICD10"/><TargetEntity id="10029864" type="MEDDRA"/><TargetEntity id="1990" type="siCondition"/></SourceEntity><SourceEntity id="668" type="ciIndication"><TargetEntity id="M62.81" type="ICD10"/><TargetEntity id="10028372" type="MEDDRA"/><TargetEntity id="D018908" type="MeSH"/><TargetEntity id="-880109541" type="omicsDisease"/><TargetEntity id="157" type="siCondition"/></SourceEntity><SourceEntity id="727" type="ciIndication"><TargetEntity id="G12" type="ICD10"/><TargetEntity id="10041582" type="MEDDRA"/><TargetEntity id="D009134" type="MeSH"/><TargetEntity id="-1479956298" type="omicsDisease"/><TargetEntity id="1242" type="siCondition"/></SourceEntity><SourceEntity id="848" type="ciIndication"><TargetEntity id="G70.0" type="ICD10"/><TargetEntity id="10028417" type="MEDDRA"/><TargetEntity id="D009157" type="MeSH"/><TargetEntity id="589" type="ORPHANET"/><TargetEntity id="-824672049" type="omicsDisease"/><TargetEntity id="158" type="siCondition"/></SourceEntity><SourceEntity id="633" type="Action"><TargetEntity id="20" type="Mechanism">Acetylcholine Release Enhancers</TargetEntity></SourceEntity><SourceEntity id="314" type="Action"><TargetEntity id="367" type="Mechanism">Potassium Channel Blockers</TargetEntity><TargetEntity id="4392" type="Mechanism">Potassium Channel Subfamily K Blockers</TargetEntity><TargetEntity id="1642" type="Mechanism">Calcium-Activated K(Ca) Channel Blockers</TargetEntity><TargetEntity id="372" type="Mechanism">K(ATP) Channel Blockers</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Lambert-Eaton syndrome - EU - Apr-2010</FirstLaunched><FirstLaunched>Lambert-Eaton syndrome - Germany - Apr-2010</FirstLaunched><FirstLaunched>Lambert-Eaton syndrome - UK - Apr-2010</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2699">Lambert-Eaton syndrome</Indication><Indication id="3252">Nystagmus</Indication><Indication id="668">Muscle weakness</Indication><Indication id="727">Spinal muscular atrophy</Indication><Indication id="848">Myasthenia gravis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1836">Orthostatic hypotension</Indication><Indication id="213">Multiple sclerosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="314">Potassium channel inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="633">Acetylcholine release stimulator</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-19T09:17:37.000Z</LastModificationDate><ChangeDateLast>2019-06-03T00:00:00.000Z</ChangeDateLast><AddedDate>2007-09-21T17:11:12.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="25861" linkType="Company"&gt;BioMarin&lt;/ulink&gt; and licensee &lt;ulink linkID="30089" linkType="Company"&gt;Catalyst Pharmaceutical&lt;/ulink&gt; have developed and launched amifampridine  phosphate   (3,4-diaminopyridine; 3,4-DAP; Zenas; Firdapse), a presynaptic potassium channel blocker which prolongs the action potential and thereby increases presynaptic calcium concentrations resulting in acetylcholine release potentiation [&lt;ulink linkID="1051903" linkType="Reference"&gt;1051903&lt;/ulink&gt;], [&lt;ulink linkID="1073268" linkType="Reference"&gt;1073268&lt;/ulink&gt;], [&lt;ulink linkID="1091634" linkType="Reference"&gt;1091634&lt;/ulink&gt;]. The drug is indicated in the US and EU for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults [&lt;ulink linkID="2003502" linkType="Reference"&gt;2003502&lt;/ulink&gt;], [&lt;ulink linkID="2100230" linkType="Reference"&gt;2100230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Beginning in April 2010 in the UK and Germany, amifampridine  phosphate was launched on a country-by-country basis in Europe, indicated for the treatment of LEMS [&lt;ulink linkID="1091634" linkType="Reference"&gt;1091634&lt;/ulink&gt;], [&lt;ulink linkID="1529567" linkType="Reference"&gt;1529567&lt;/ulink&gt;].  In January 2019,  the drug was launched in the US for the treatment of LEMS in adults [&lt;ulink linkID="2123497" linkType="Reference"&gt;2123497&lt;/ulink&gt;], [&lt;ulink linkID="2151118" linkType="Reference"&gt;2151118&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development for other indications is ongoing. In October 2015, a phase III  trial was initiated  in pediatric patients   with congenital myasthenic syndromes (CMS) [&lt;ulink linkID="1700283" linkType="Reference"&gt;1700283&lt;/ulink&gt;], [&lt;ulink linkID="1700820" linkType="Reference"&gt;1700820&lt;/ulink&gt;]; in December 2016, the  study was expanded  to include adult CMS patients [&lt;ulink linkID="1883705" linkType="Reference"&gt;1883705&lt;/ulink&gt;]; in March 2018, data were expected in 1H19 [&lt;ulink linkID="2015473" linkType="Reference"&gt;2015473&lt;/ulink&gt;]; in May 2019, clinical development in CMS was ongoing [&lt;ulink linkID="2157810" linkType="Reference"&gt;2157810&lt;/ulink&gt;].. In February 2016, Catalyst supported the initiation of an investigator-sponsored phase II/III trial   in myasthenia gravis (MG) caused by antibodies to the muscle-specific receptor tyrosine kinase (MuSK)   [&lt;ulink linkID="1733733" linkType="Reference"&gt;1733733&lt;/ulink&gt;], [&lt;ulink linkID="1743920" linkType="Reference"&gt;1743920&lt;/ulink&gt;]; in March 2017, positive topline data were reported [&lt;ulink linkID="1908846" linkType="Reference"&gt;1908846&lt;/ulink&gt;]. In April 2018, a company-sponsored phase III in patients with MuSK antibody positive MG was initiated [&lt;ulink linkID="2025423" linkType="Reference"&gt;2025423&lt;/ulink&gt;]; in August 2018, topline data were expected in 2H19 [&lt;ulink linkID="2060973" linkType="Reference"&gt;2060973&lt;/ulink&gt;]; in May 2019, clinical development in MuSK-MG was ongoing [&lt;ulink linkID="2157810" linkType="Reference"&gt;2157810&lt;/ulink&gt;]. In December 2014, the drug was listed as being in phase II development for downbeat nystagmus [&lt;ulink linkID="1617062" linkType="Reference"&gt;1617062&lt;/ulink&gt;]. In November 2017, a company-sponsored phase II trial was initiated for the symptomatic treatment of ambulatory patients with spinal muscular atrophy (SMA) Type 3 [&lt;ulink linkID="1984613" linkType="Reference"&gt;1984613&lt;/ulink&gt;]; in March 2019, topline data were expected in the first half of 2020   [&lt;ulink linkID="2130972" linkType="Reference"&gt;2130972&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;AP-HP was  previously investigating the drug for multiple sclerosis, for which phase III trials began in February 2005  [&lt;ulink linkID="832753" linkType="Reference"&gt;832753&lt;/ulink&gt;].  In October 2009, BioMarin stated that it intended to continue to evaluate development for this indication [&lt;ulink linkID="1051903" linkType="Reference"&gt;1051903&lt;/ulink&gt;]. However no further development has since been reported. By April 2012, a clinical study of the drug for orthostatic hypotension had been completed [&lt;ulink linkID="1282964" linkType="Reference"&gt;1282964&lt;/ulink&gt;]; however, no  further development has since been reported.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="17320" linkType="Company"&gt;Jacobus Pharmaceuticals&lt;/ulink&gt; is also developing a different formulation of &lt;ulink linkID="92213" linkType="Drug"&gt;amifampridine&lt;/ulink&gt; (3,4-diaminopyridine, DAP) for the treatment of LEMS [&lt;ulink linkID="1643002" linkType="Reference"&gt;1643002&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In February 2013, BioMarin stated that it had patent protection for amifampridine  phosphate in the EU for LEMS, and that Orphan Drug exclusivity expires in the EU in December 2019; at that time, no US patents had yet been issued   [&lt;ulink linkID="1392786" linkType="Reference"&gt;1392786&lt;/ulink&gt;].  In February 2015, the company stated that EU patent protection was to expire in 2022  [&lt;ulink linkID="1641430" linkType="Reference"&gt;1641430&lt;/ulink&gt;], [&lt;ulink linkID="1091623" linkType="Reference"&gt;1091623&lt;/ulink&gt;]. In February 2016,US patents were still pending [&lt;ulink linkID="1745315" linkType="Reference"&gt;1745315&lt;/ulink&gt;]; in March 2016, Catalyst noted that it licensed two pending patent applications from BioMarin. One of these was a composition of matter patent  application awaiting substantive examination after being previously rejected several times by office actions; the composition of matter patent is slated to expire, subject to issuance, in February 2027 (including an expected 5-year patent term extension). The second patent covered methods of administering the drug; by that time, no examination on this patent had occurred and none was expected until the end of 2016  [&lt;ulink linkID="1743920" linkType="Reference"&gt;1743920&lt;/ulink&gt;]. In March 2018, these patents remained pending [&lt;ulink linkID="2015473" linkType="Reference"&gt;2015473&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In March 2017, the company planned to meet with the FDA to conduct a registration trial in the US for patients with MuSK-antibody-positive myasthenia gravis [&lt;ulink linkID="1908846" linkType="Reference"&gt;1908846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2014, an expanded access program had been initiated for LEMS, CMS, and downbeat nystagmus [&lt;ulink linkID="1617062" linkType="Reference"&gt;1617062&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, a Type B meeting was held with the FDA, in which Catalyst summarized its preclinical and clinical studies in LEMS, and manufacturing information, and the FDA agreed that the development program was on track for a nearly complete NDA pending further in vitro data [&lt;ulink linkID="1513179" linkType="Reference"&gt;1513179&lt;/ulink&gt;]. At that time, data from a  QT study were presented; these had been requested by the FDA at a pre-IND meeting in 2010 to be included as part of the clinical safety package [&lt;ulink linkID="1513951" linkType="Reference"&gt;1513951&lt;/ulink&gt;]. By February 2015, Catalyst had held a pre-NDA meeting with the FDA [&lt;ulink linkID="1630616" linkType="Reference"&gt;1630616&lt;/ulink&gt;]; potential approval pathways were discussed to include CMS as an additional indication [&lt;ulink linkID="1643002" linkType="Reference"&gt;1643002&lt;/ulink&gt;]. In July 2015, a rolling NDA was initiated for the treatment of LEMS [&lt;ulink linkID="1679764" linkType="Reference"&gt;1679764&lt;/ulink&gt;]. In October 2015, the NDA was to include results observed in children and new pediatric  data  from ongoing  trials [&lt;ulink linkID="1700820" linkType="Reference"&gt;1700820&lt;/ulink&gt;]. In December 2015, Catalyst completed its rolling NDA submission for LEMS and CMS, with a request for Priority Review [&lt;ulink linkID="1722334" linkType="Reference"&gt;1722334&lt;/ulink&gt;]. In February 2016, the company had received a Refusal to File letter from the  FDA regarding its NDA, finding that the filing was incomplete and requesting further information [&lt;ulink linkID="1735550" linkType="Reference"&gt;1735550&lt;/ulink&gt;]. In April 2016, the FDA stated that in addition to the data from the phase III LMS-002 trial, it would require data from an additional adequate and well-controlled LEMS study, plus from several short-term toxicology studies [&lt;ulink linkID="1756235" linkType="Reference"&gt;1756235&lt;/ulink&gt;]; in June 2016, the design of a phase III confirmatory trial in LEMS was agreed with the FDA [&lt;ulink linkID="1772173" linkType="Reference"&gt;1772173&lt;/ulink&gt;]. In October 2016, the FDA agreed an SPA for the additional trial [&lt;ulink linkID="1868833" linkType="Reference"&gt;1868833&lt;/ulink&gt;]. In August 2017, Catalyst intended to request a confirmatory pre-NDA meeting with the FDA to discuss the proposed NDA filing package   [&lt;ulink linkID="1957563" linkType="Reference"&gt;1957563&lt;/ulink&gt;].  In February 2018, Catalyst concluded a Type C meeting with the FDA. Prior to the meeting, Catalyst provided the FDA with its preliminary data package for the proposed NDA resubmission, including the results of the additional LMS-003 trial [&lt;ulink linkID="2004540" linkType="Reference"&gt;2004540&lt;/ulink&gt;]. In March 2018, Catalyst submitted an NDA to the FDA for the symptomatic treatment of LEMS, addressing the issues raised in the 2016 Refusal to File letter. The company also reported its decision not to include CMS indication in the resubmission, instead planning to file in this setting at a later date pending positive trial data [&lt;ulink linkID="2018295" linkType="Reference"&gt;2018295&lt;/ulink&gt;]. In May 2018, the FDA accepted  the NDA for a Priority Review and a PDUFA date was set for November 28, 2018. The filing was based on positive data from two phase III studies [&lt;ulink linkID="2038286" linkType="Reference"&gt;2038286&lt;/ulink&gt;]. In November 2018, the FDA approved the drug for the treatment of LEMS in adults; launch  was expected  in 1Q19  [&lt;ulink linkID="2099610" linkType="Reference"&gt;2099610&lt;/ulink&gt;], [&lt;ulink linkID="2100165" linkType="Reference"&gt;2100165&lt;/ulink&gt;], [&lt;ulink linkID="2100105" linkType="Reference"&gt;2100105&lt;/ulink&gt;], [&lt;ulink linkID="2100983" linkType="Reference"&gt;2100983&lt;/ulink&gt;]. In January 2019,  the drug was launched in the US for the treatment of LEMS in adults [&lt;ulink linkID="2123497" linkType="Reference"&gt;2123497&lt;/ulink&gt;], [&lt;ulink linkID="2151118" linkType="Reference"&gt;2151118&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, the FDA granted Orphan Drug status for LEMS [&lt;ulink linkID="1060845" linkType="Reference"&gt;1060845&lt;/ulink&gt;]. In August 2013, amifampridine phosphate was granted Breakthrough Therapy Designation by the FDA for the symptomatic treatment of LEMS [&lt;ulink linkID="1470112" linkType="Reference"&gt;1470112&lt;/ulink&gt;]. In March 2015, the drug was  granted Orphan Drug status for CMS [&lt;ulink linkID="1639288" linkType="Reference"&gt;1639288&lt;/ulink&gt;]. In August 2016, amifampridine phosphate was granted Orphan designation by the FDA for the treatment of myasthenia gravis [&lt;ulink linkID="1793138" linkType="Reference"&gt;1793138&lt;/ulink&gt;], [&lt;ulink linkID="1793312" linkType="Reference"&gt;1793312&lt;/ulink&gt;]. In November 2017, Catalyst planned to submit an application for Orphan designation for the treatment of ambulatory patients with SMA Type 3, if data from a phase II trial were positive [&lt;ulink linkID="1984613" linkType="Reference"&gt;1984613&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In June 2008, the EMEA began a review, and in October 2009, the EMA's CHMP adopted a positive opinion, recommending the drug be granted approval for LEMS under 'exceptional circumstances' [&lt;ulink linkID="1051559" linkType="Reference"&gt;1051559&lt;/ulink&gt;], [&lt;ulink linkID="1053776" linkType="Reference"&gt;1053776&lt;/ulink&gt;].  In December 2009, the EC approved amifampridine for LEMS, and the drug was to be launched on a country by country basis [&lt;ulink linkID="1267227" linkType="Reference"&gt;1267227&lt;/ulink&gt;]. In April 2010, the drug was launched in the UK and Germany [&lt;ulink linkID="1091634" linkType="Reference"&gt;1091634&lt;/ulink&gt;], [&lt;ulink linkID="1091623" linkType="Reference"&gt;1091623&lt;/ulink&gt;]. In June 2010, the drug was launched in France [&lt;ulink linkID="1349125" linkType="Reference"&gt;1349125&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2006, Orphan Drug status for LEMS had been granted in the EU [&lt;ulink linkID="832740" linkType="Reference"&gt;832740&lt;/ulink&gt;]. In November 2009, the CHMP of the EMA recommended that the drug keep its Orphan Drug status for LEMS [&lt;ulink linkID="1056283" linkType="Reference"&gt;1056283&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In May 2019, licensee Catalyst  planned to submit an application for    Orphan Drug status for LEMS  for the drug in Japan [&lt;ulink linkID="2157810" linkType="Reference"&gt;2157810&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Lambert-Eaton myasthenic syndrome&lt;/subtitle&gt;In June 2016, a small, single-center, phase III confirmatory trial for the symptomatic treatment of LEMS was expected to start in 2H16  [&lt;ulink linkID="1772173" linkType="Reference"&gt;1772173&lt;/ulink&gt;]. In October 2016, the FDA agreed an SPA for the double-blind, placebo controlled, withdrawal, parallel-design phase III  trial (LMS-003) in LEMS patients (expected n = 28) in the US. The trial would enroll patients from the drug's expanded access program [&lt;ulink linkID="1868833" linkType="Reference"&gt;1868833&lt;/ulink&gt;]. In November 2016, the phase III trial (&lt;ulink linkID="279883" linkType="Protocol"&gt;NCT02970162&lt;/ulink&gt;) began. The primary endpoint was the change from baseline in Quantitative Myasthenia Gravis (QMG) and in Subject Global Impression (SGI) scores at end of day 4. At that time, the trial was expected to complete in September 2017   [&lt;ulink linkID="1886027" linkType="Reference"&gt;1886027&lt;/ulink&gt;]. In December 2016, the first patient was enrolled. [&lt;ulink linkID="1885830" linkType="Reference"&gt;1885830&lt;/ulink&gt;]. In October 2017, enrollment of 26 patients was completed [&lt;ulink linkID="1976580" linkType="Reference"&gt;1976580&lt;/ulink&gt;]. In November 2017, data from the 26-patient trial were reported, which showed that amifampridine phosphate achieved significance versus placebo in the QMG (p = 0.0004) and SGI (p = 0.0003) scores statistically; a difference of 6.4 points was observed between the treatment group and placebo groups for QMG [&lt;ulink linkID="1985639" linkType="Reference"&gt;1985639&lt;/ulink&gt;]. In February 2019, further data were published. At day 4, mean physician's clinical global impression of improvement (CGI-I)  scores were 3.8 versus 5.5 for amifampridine phosphate versus placebo, respectively (p=0.002). Additionally, at day 4 the proportion of patients with a &amp;gt;/=20% increase in the 3TUG (timed up and go) test average time was significantly higher (p=0.0112) for placebo (61.5%) compared with amifampridine phosphate (7.7%); and the treatment differences in LS mean values was 3.29 (p&amp;gt;0.0001) for QMG-LD score (the total sum of right and left arm and leg raising maneuvers in QMG) [&lt;ulink linkID="2123497" linkType="Reference"&gt;2123497&lt;/ulink&gt;], [&lt;ulink linkID="2123361" linkType="Reference"&gt;2123361&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In June 2011, a multinational, randomized, double-blind, placebo-controlled,  phase III, discontinuation study (&lt;ulink linkID="78480" linkType="Protocol"&gt;NCT01377922&lt;/ulink&gt;; EudraCT: 2010-021850-20; LMS-002) was initiated in the US and Europe, to evaluate the efficacy and long-term safety of amifampridine phosphate in the treatment of patients (expected n = 30) with LEMS. Patients were to be treated with amifampridine phosphate for at least 91 days, then randomized to either continue with the drug or be discontinued to placebo for 2 weeks, and following randomization would receive open-label amifampridine phosphate treatment for 2 years. The primary endpoint was the change from baseline in Quantitative Myasthenia Gravis and in Subject Global Impression scores. The secondary endpoint was the timed 25-foot walk test. At that time, the study was expected to complete in August 2012; in July 2016, the trial completed  [&lt;ulink linkID="1198377" linkType="Reference"&gt;1198377&lt;/ulink&gt;], [&lt;ulink linkID="1275344" linkType="Reference"&gt;1275344&lt;/ulink&gt;]. In March 2013, the Data Monitoring Committee (DMC) recommended continuation of the trial  [&lt;ulink linkID="1396745" linkType="Reference"&gt;1396745&lt;/ulink&gt;]. In October 2013, following a further review, the DMC recommended that the trial continue as planned [&lt;ulink linkID="1488268" linkType="Reference"&gt;1488268&lt;/ulink&gt;]. In January 2014, the FDA requested a modification to the analyses of endpoints, which the company considered would not impact data collection or the number of patients enrolled [&lt;ulink linkID="1513179" linkType="Reference"&gt;1513179&lt;/ulink&gt;]. In March 2014, the DMC recommended that the trial continue as planned; at that time, the trial was also being conducted in Canada and South America [&lt;ulink linkID="1538808" linkType="Reference"&gt;1538808&lt;/ulink&gt;]. In April 2014, target enrollment was achieved, which would allow for 36 patients to be randomized in the discontinuation portion of the trial. At that time, further patients were  screened  [&lt;ulink linkID="1541644" linkType="Reference"&gt;1541644&lt;/ulink&gt;]. In August 2014, the last patient completed the blinded part of the trial. A total of 38 completed the 3-month treatment stage, and all 38 elected to join the 2-year open-label follow-up [&lt;ulink linkID="1584566" linkType="Reference"&gt;1584566&lt;/ulink&gt;]. In September 2014, topline data were reported demonstrating that the coprimary endpoints were met. At day 14, the changes in quantitative myasthenia gravis score and subject global impression were significantly different from placebo, with clinically significant worsening of 2.2 and 2.6 points, respectively, observed in the placebo group. Significant differences compared with placebo were also observed for the secondary endpoints of the CGI-I and the  timed 25-foot walk test, with a clinically significant observation in the CGI-I at day 14 of 4.7 points in the placebo group and a worsening of walking speed at day 14 of 9.67 ft/min for placebo [&lt;ulink linkID="1598426" linkType="Reference"&gt;1598426&lt;/ulink&gt;].  ​In April 2015, similar data were presented at the 67th AAN Annual Meeting in Washington DC [&lt;ulink linkID="1651908" linkType="Reference"&gt;1651908&lt;/ulink&gt;]. These data were published in May 2016 [&lt;ulink linkID="1763607" linkType="Reference"&gt;1763607&lt;/ulink&gt;]. In May 2016, further data were presented at the Second EAN Congress in Copenhagen, Denmark. At day 14, compared to amifampridine phosphate, placebo patients had a greater worsening of symptoms in quantitative myasthenia gravis, subjective global impression and clinical global impression  scores, respectively. Compared to amifampridine phosphate, placebo patients had clinically significant disease progression at day 8  but not by day 14. Drug-related serious adverse events were not observed and the treatment was generally well tolerated. Drug related side effects like paraesthesia, gastrointestinal disorders and infections were observed [&lt;ulink linkID="1789706" linkType="Reference"&gt;1789706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, data were published from a double-blind, placebo-controlled, randomized, cross-over trial in patients (n = 7) with LEMS; amifampridine  phosphate significantly improved the subjective symptoms score, LEMS classification, muscle strength score, quantitative myasthenia gravis score and compound-muscle-action potential amplitudes compared with placebo [&lt;ulink linkID="1512254" linkType="Reference"&gt;1512254&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, data were published from a double-blind, placebo-controlled, cross-over, double-dummy trial in patients (n = 9) with LEMS; amifampridine  phosphate significantly improved isometric muscle strength and the resting compound-muscle-action potential amplitudes compared with placebo [&lt;ulink linkID="1512253" linkType="Reference"&gt;1512253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2000, data were published from a prospective, placebo-controlled, randomized, parallel-group trial in patients (n = 26) with LEMS; amifampridine  phosphate significantly improved the quantitative myasthenia gravis score and the resting compound-muscle-action potential amplitudes compared with placebo [&lt;ulink linkID="1153748" linkType="Reference"&gt;1153748&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1989, data were published from a double-blind, placebo-controlled, cross-over trial in patients (n = 12) with LEMS; amifampridine  phosphate (up to 100 mg/day) increased muscle strength from 70 to 81% of normal in the upper extremities, and from 45 to 65% of normal in the lower extremities. The amplitudes of compound-muscle-action potentials increased from 2.9 to 5.0 mV in the arm and from 1.6 to 3.1 mV in the leg [&lt;ulink linkID="1512251" linkType="Reference"&gt;1512251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Congenital myasthenic syndromes&lt;/subtitle&gt;In October 2015, a randomized, double-blind, outpatient-crossover-assigned, placeobo-controlled, phase III trial (&lt;ulink linkID="241781" linkType="Protocol"&gt;NCT02562066&lt;/ulink&gt;; CMS-001) was intiated in pediatric patients aged 2 to 17 years (expected n = 10) with CMS to evaluate the safety and efficacy of amifampridine phosphate. The trial was expected to be completed in July 2016 [&lt;ulink linkID="1700283" linkType="Reference"&gt;1700283&lt;/ulink&gt;], [&lt;ulink linkID="1700820" linkType="Reference"&gt;1700820&lt;/ulink&gt;]; following completion of the trial, amifampridine phosphate would be made available to patients in the expanded access program [&lt;ulink linkID="1700820" linkType="Reference"&gt;1700820&lt;/ulink&gt;]. In August 2016, top-line data were expected in 2H17 [&lt;ulink linkID="1786976" linkType="Reference"&gt;1786976&lt;/ulink&gt;]. In December 2016, the  study was expanded  to include adult CMS patients, with enrollment size increased to 20 patients [&lt;ulink linkID="1883705" linkType="Reference"&gt;1883705&lt;/ulink&gt;]. In August 2017, topline data were expected in 1H18 [&lt;ulink linkID="1957563" linkType="Reference"&gt;1957563&lt;/ulink&gt;]. In March 2018, enrollment was expected to be completed before the end of 2018 and top-line results were expected in 1H19; at that time, the trial was expected to complete in December 2018 [&lt;ulink linkID="2015473" linkType="Reference"&gt;2015473&lt;/ulink&gt;]. In November 2018, patient enrollment was expected to complete  soon and top-line results were expected in the second half of 2019 [&lt;ulink linkID="2091967" linkType="Reference"&gt;2091967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Multiple sclerosis&lt;/subtitle&gt;In February 2005, a placebo-controlled, randomized, double-blind, parallel assignment, phase III trial (&lt;ulink linkID="7632" linkType="Protocol"&gt;NCT00190268&lt;/ulink&gt;; P020304; GER02009) was initiated by AP-HP in patients  (expected n = 126) with multiple sclerosis, for  fatigue associated with the condition in France.  The primary endpoint was improvement of fatigue measured by a decrease of EMIF-SEP score, compared to placebo, and secondary endpoints included safety and quality of life improvement. The study was expected to complete in May 2008 [&lt;ulink linkID="832753" linkType="Reference"&gt;832753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Orthostatic hypotension&lt;/subtitle&gt;In April 2012, data were presented at the 64th AAN Annual Meeting in New Orleans, LA, from a placebo-controlled, blinded, pilot study of amifampridine  phosphate in orthostatic hypotension patients (n=11). A significant improvement in orthostatic blood pressure and symptoms was seenin patients receiving treatment. The drug was reported to be safe and well tolerated. At that time, the trial was completed and a large, randomized, double-blind, placebo-controlled trial was planned to confirm results [&lt;ulink linkID="1282964" linkType="Reference"&gt;1282964&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Myasthenia gravis&lt;/subtitle&gt;In March 2017, the company planned to meet with the FDA to initiate a registration trial in the US for patients with MuSK-antibody-positive myasthenia gravis [&lt;ulink linkID="1908846" linkType="Reference"&gt;1908846&lt;/ulink&gt;]. In August 2017, Catalyst reached an agreement with the FDA under a SPA for the trial design, clinical endpoints and statistical analysis approach for the trial. The trial would be a multicenter, double-blind, placebo-controlled, trial conducted in the US and Italy and expected to enroll 60 subjects. The trial would also enroll up to 10 generalized myasthenia gravis patients, as requested by the FDA, to be assessed with the same clinical endpoints, but achieving statistical significance in this subgroup of patients was not required. The primary endpoint was Myasthenia Gravis Activities of Daily Living (MG-ADL). At that time,  completion of enrollment was expected to take 12 months  [&lt;ulink linkID="1957563" linkType="Reference"&gt;1957563&lt;/ulink&gt;]. In Jnauary 2018, the randomized, parallel-group phase III trial  (&lt;ulink linkID="315215" linkType="Protocol"&gt;NCT03304054&lt;/ulink&gt;; MSK-002) was initiated in the US. In March 2018, topline data were expected in 1H19. At that time, the study was to complete in February 2019 [&lt;ulink linkID="2015473" linkType="Reference"&gt;2015473&lt;/ulink&gt;], [&lt;ulink linkID="2025557" linkType="Reference"&gt;2025557&lt;/ulink&gt;]. In April 2018, the first patient was enrolled  [&lt;ulink linkID="2025423" linkType="Reference"&gt;2025423&lt;/ulink&gt;]. In August 2018, topline data were expected in 2H19 [&lt;ulink linkID="2060973" linkType="Reference"&gt;2060973&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, an investigator-sponsored, randomized (1:1), double-blind, placebo-controlled, crossover, phase II/III outpatient study (EudraCT: &lt;ulink linkID="291629" linkType="Protocol"&gt;2015-003127-62&lt;/ulink&gt;) was initiated in Italy to evaluate the safety, tolerability and  efficacy of amifampridine as a symptomatic treatment for patients (expected n = 20) with MuSK-antibody-positive myasthenia gravis [&lt;ulink linkID="1733733" linkType="Reference"&gt;1733733&lt;/ulink&gt;], [&lt;ulink linkID="1743920" linkType="Reference"&gt;1743920&lt;/ulink&gt;], [&lt;ulink linkID="2076321" linkType="Reference"&gt;2076321&lt;/ulink&gt;]. In March 2017, topline data from the 7-patient trial were reported. The co-primary efficacy endpoints of change from baseline in total QMG score and total MG-ADL score were statistically and clinically significant (p=0.0003 and p=0.0006, respectively). Amifampridine phosphate also demonstrated a favorable tolerability profile [&lt;ulink linkID="1908846" linkType="Reference"&gt;1908846&lt;/ulink&gt;], [&lt;ulink linkID="1909607" linkType="Reference"&gt;1909607&lt;/ulink&gt;]. In December  2018,  the full trial results were published  [&lt;ulink linkID="2108499" linkType="Reference"&gt;2108499&lt;/ulink&gt;], [&lt;ulink linkID="2108364" linkType="Reference"&gt;2108364&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spinal muscular atrophy&lt;/subtitle&gt;In November 2017, a Catalyst-sponsored, double-blind, two-period, two-treatment, crossover, outpatient proof-of-concept, phase II trial was initiated to evaluate the safety, tolerability and efficacy of amifampridine phosphate as a symptomatic treatment for ambulatory patients (expected n = 12) with SMA Type 3. The trial would be conducted by researchers in Italy. At that time, topline data were expected in 1H19 [&lt;ulink linkID="1984613" linkType="Reference"&gt;1984613&lt;/ulink&gt;]. In March 2018, the first subject was expected to be enrolled in 2H18 [&lt;ulink linkID="2013970" linkType="Reference"&gt;2013970&lt;/ulink&gt;]. Also in March 2018, topline data were expected in 2H19 [&lt;ulink linkID="2015473" linkType="Reference"&gt;2015473&lt;/ulink&gt;]. By March 2019, the first patient was enrolled in the trial and total enrollment was expected to complete before the end of 2019. At that time, top-line data were expected  in the first half of 2020   [&lt;ulink linkID="2130972" linkType="Reference"&gt;2130972&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;By March 2017, short-term toxicology studies had been initiated [&lt;ulink linkID="1909607" linkType="Reference"&gt;1909607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, data were presented at the 66th annual meeting of the American Academy of Neurology, held in Philadelphia, PA [&lt;ulink linkID="1557969" linkType="Reference"&gt;1557969&lt;/ulink&gt;] &lt;/para&gt;&lt;para&gt;By March 2014, a safety and tolerability  trial of amifampridine phosphate in patients with renal (kidney) impairment was initiated [&lt;ulink linkID="1557969" linkType="Reference"&gt;1557969&lt;/ulink&gt;]. In January 2015, the renal safety study and full toxicology program for amifampridine phosphate were expected to complete in 2Q15 [&lt;ulink linkID="1625977" linkType="Reference"&gt;1625977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2010, at a pre-IND meeting, the FDA requested results from a thorough QT study of amifampridine phosphate at or above therapeutic concentrations. In January 2014, data were reported from a randomized, double-blind cardiac safety study comparing the effects of amifampridine phosphate at or above therapeutic concentrations to placebo on the QT interval in healthy volunteers (n = 59). The study met the pre-specified primary endpoint of whether amifampridine phosphate differed from placebo in the mean change in the QTc interval, demonstrating that there was no effect of amifampridine phosphate on heart rate or cardiac depolarization [&lt;ulink linkID="1513951" linkType="Reference"&gt;1513951&lt;/ulink&gt;]. In January 2015, the full toxicology program for amifampridine phosphate were expected to complete in 2Q15 [&lt;ulink linkID="1625977" linkType="Reference"&gt;1625977&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By August 2017, Catalyst was conducting three preclinical abuse liability studies required by the FDA's guidance for 'Assessment of Abuse Potential of Drugs'. By that time, Catalyst had completed the studies for self-administration and physical dependence, and obtained topline results indicating that amifampridine phosphate does not exhibit abuse liability.  The third study for drug discrimination was ongoing and expected to be complete in 4Q17 [&lt;ulink linkID="1957563" linkType="Reference"&gt;1957563&lt;/ulink&gt;]. By November 2017,  abuse liability studies had been completed [&lt;ulink linkID="1980013" linkType="Reference"&gt;1980013&lt;/ulink&gt;]. In March 2018, it was reported that results indicated that amifampridine phosphate did not exhibit abuse potential in the assessment models [&lt;ulink linkID="2015473" linkType="Reference"&gt;2015473&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2010-06-24T00:00:00.000Z</StatusDate><Source id="1349125" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2010-04-19T00:00:00.000Z</StatusDate><Source id="1091623" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2010-04-19T00:00:00.000Z</StatusDate><Source id="1091623" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2019-01-15T00:00:00.000Z</StatusDate><Source id="2151118" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2010-04-19T00:00:00.000Z</StatusDate><Source id="1091623" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="848">Myasthenia gravis</Indication><StatusDate>2018-04-19T00:00:00.000Z</StatusDate><Source id="2025423" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="848">Myasthenia gravis</Indication><StatusDate>2016-02-08T00:00:00.000Z</StatusDate><Source id="1733733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2014-03-25T00:00:00.000Z</StatusDate><Source id="1538808" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="668">Muscle weakness</Indication><StatusDate>2015-10-06T00:00:00.000Z</StatusDate><Source id="1617062" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3252">Nystagmus</Indication><StatusDate>2014-12-02T00:00:00.000Z</StatusDate><Source id="1617062" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="727">Spinal muscular atrophy</Indication><StatusDate>2017-11-21T00:00:00.000Z</StatusDate><Source id="1984613" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2019-05-30T00:00:00.000Z</StatusDate><Source id="2157810" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2018-01-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1836">Orthostatic hypotension</Indication><StatusDate>2013-10-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2012-10-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2012-10-26T00:00:00.000Z</StatusDate><Source id="1909607" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23948">Assistance Publique Hopitaux de Paris</Company><Country id="FR">France</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2006-05-22T00:00:00.000Z</StatusDate><Source id="832740" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23948">Assistance Publique Hopitaux de Paris</Company><Country id="FR">France</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2006-05-22T00:00:00.000Z</StatusDate><Source id="832740" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031239">EUSA Pharma USA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2009-10-26T00:00:00.000Z</StatusDate><Source id="1051559" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1031239">EUSA Pharma USA</Company><Country id="FR">France</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2009-10-26T00:00:00.000Z</StatusDate><Source id="1051559" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1836">Orthostatic hypotension</Indication><StatusDate>2012-10-26T00:00:00.000Z</StatusDate><Source id="1909607" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2011-06-07T00:00:00.000Z</StatusDate><Source id="1198377" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1836">Orthostatic hypotension</Indication><StatusDate>2012-04-25T00:00:00.000Z</StatusDate><Source id="1282964" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2009-10-26T00:00:00.000Z</StatusDate><Source id="1051903" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1267227" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="668">Muscle weakness</Indication><StatusDate>2014-12-02T00:00:00.000Z</StatusDate><Source id="1617062" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="668">Muscle weakness</Indication><StatusDate>2015-12-17T00:00:00.000Z</StatusDate><Source id="1722334" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2012-10-26T00:00:00.000Z</StatusDate><Source id="1909607" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="848">Myasthenia gravis</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1793138" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2014-03-25T00:00:00.000Z</StatusDate><Source id="1538808" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1836">Orthostatic hypotension</Indication><StatusDate>2012-10-26T00:00:00.000Z</StatusDate><Source id="1909607" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2015-07-22T00:00:00.000Z</StatusDate><Source id="1679764" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2018-11-28T00:00:00.000Z</StatusDate><Source id="2099610" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23948">Assistance Publique Hopitaux de Paris</Company><Country id="FR">France</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2006-05-21T00:00:00.000Z</StatusDate><Source id="832740" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28650">OPi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2006-05-22T00:00:00.000Z</StatusDate><Source id="832740" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23948">Assistance Publique Hopitaux de Paris</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2005-02-28T00:00:00.000Z</StatusDate><Source id="832753" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28650">OPi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2007-09-21T00:00:00.000Z</StatusDate><Source id="832374" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28650">OPi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2008-05-09T00:00:00.000Z</StatusDate><Source id="904255" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28650">OPi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2007-09-21T00:00:00.000Z</StatusDate><Source id="832374" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1050402">Huxley Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2009-10-26T00:00:00.000Z</StatusDate><Source id="1051559" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031239">EUSA Pharma USA</Company><Country id="FR">France</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2007-09-21T00:00:00.000Z</StatusDate><Source id="832374" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1031239">EUSA Pharma USA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2008-05-09T00:00:00.000Z</StatusDate><Source id="904255" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2009-10-26T00:00:00.000Z</StatusDate><Source id="1051559" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2699">Lambert-Eaton syndrome</Indication><StatusDate>2009-10-26T00:00:00.000Z</StatusDate><Source id="1051903" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="30089">Catalyst Pharmaceutical Partners Inc</OwnerCompany><Country id="US">US</Country><Indication id="2699">Lambert-Eaton syndrome</Indication><AwardedIndication>Symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-08-27T00:00:00.000Z</MileStoneDate><Source id="1470112" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30089">Catalyst Pharmaceutical Partners Inc</OwnerCompany><Country id="US">US</Country><Indication id="848">Myasthenia gravis</Indication><AwardedIndication>Treatment of myasthenia gravis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-08-31T00:00:00.000Z</MileStoneDate><Source id="1793312" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30089">Catalyst Pharmaceutical Partners Inc</OwnerCompany><Country id="US">US</Country><Indication id="848">Myasthenia gravis</Indication><AwardedIndication>Treatment of congenital myasthenic syndromes</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-03-03T00:00:00.000Z</MileStoneDate><Source id="1639288" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2699">Lambert-Eaton syndrome</Indication><AwardedIndication>Treatment of Lambert-Eaton myasthenic syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2010-06-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30089">Catalyst Pharmaceutical Partners Inc</OwnerCompany><Country id="US">US</Country><Indication id="2699">Lambert-Eaton syndrome</Indication><AwardedIndication>Treatment of Lambert-Eaton Myasthenic Syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2009-11-12T00:00:00.000Z</MileStoneDate><Source id="1060845" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2699">Lambert-Eaton syndrome</Indication><AwardedIndication>Treatment of Lambert-Eaton myasthenic syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2006-04-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2699">Lambert-Eaton syndrome</Indication><AwardedIndication>Treatment of Lambert-Eaton myasthenic syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2002-12-18T00:00:00.000Z</MileStoneDate><Source id="832740" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2699">Lambert-Eaton syndrome</Indication><AwardedIndication>Treatment of Lambert-Eaton myasthenic syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2002-11-15T00:00:00.000Z</MileStoneDate><Source id="1056283" type="PR"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="30089">Catalyst Pharmaceutical Partners Inc</OwnerCompany><Country id="US">US</Country><Indication id="2699">Lambert-Eaton syndrome</Indication><AwardedIndication>Treatment of Lambert-Eaton myasthenic syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-05-29T00:00:00.000Z</MileStoneDate><Source id="2038286" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01591"><Name>Potassium channel</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2161959" linkType="reference" linkID="2161959"&gt;2161959&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1005265">Biocept Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1107183">EUSA Pharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="23948">Assistance Publique Hopitaux de Paris</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25861">BioMarin Pharmaceutical Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="30089">Catalyst Pharmaceutical Partners Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cncc(c1N)N.OP(=O)(O)O</Smiles><Smiles>c1cncc(c1N)N</Smiles></StructureSmiles><Deals><Deal id="110276" title="OPi to develop AP-HP's 3,4-diaminopyridine for LEMS worldwide"/><Deal id="128444" title="Huxley to develop EUSA Pharma's amifampridine"/><Deal id="142426" title="Catalyst to develop and commercialize BioMarin's Firdapse in North America  "/><Deal id="237245" title="Catalyst to use Biocept's target selector platform for LEMS patients in phase III Firdapse trial  "/></Deals><PatentFamilies><PatentFamily id="2440600" number="WO-2013003708" title="Methods of administering 3,4-diaminopyridine"/><PatentFamily id="645179" number="WO-02062760" title="3,4-Diaminopyridine tartrate and phosphate, pharmaceutical compositions and uses thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="EUSA Pharma" id="1107183"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Assistance Publique Hopitaux de Paris" id="23948"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioMarin Pharmaceutical Inc" id="25861"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Catalyst Pharmaceutical Partners Inc" id="30089"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>